Navigation Links
ASTRO publishes palliative radiotherapy for bone metastases guideline
Date:2/17/2011

The American Society for Radiation Oncology (ASTRO) Clinical Affairs and Quality Committee has developed a guideline for the use of radiation therapy in treating bone metastases. The guideline will be published in the International Journal of Radiation OncologyBiologyPhysics, an official journal of ASTRO.

Bone metastases are caused when a malignant tumor spreads to the bone. They can lead to debilitating effects including pain, fractures and paralysis due to spinal cord compression. The care of these patients requires collaboration between several types of cancer treatment specialists.

External beam radiation therapy (EBRT) provides successful pain relief in 50 to 80 percent of patients with little risk of side effects. However, the widespread variation in practice patterns between radiation oncologists presented an opportunity to standardize care through the construction of a formal treatment guideline.

Some of the committee's findings include:

  1. EBRT continues to be the mainstay for treating bone metastases.

  2. Both single doses and longer courses of radiation have shown similar pain relief outcomes, and each has advantages. A single course has proven more convenient for patients and caregivers, while longer courses have a lower incidence of repeat treatment to the same site.

  3. Repeat irradiation with EBRT might be feasible in some circumstances, though the details of its effectiveness and safety are still to be determined.

  4. Bisphosphonates do not eliminate the need for EBRT for painful metastases, and they act effectively when combined with EBRT.

  5. Stereotactic body radiation therapy can be considered for patients with a newly discovered or recurrent tumor in the spinal column or paraspinal areas; however, it is suggested that stereotactic treatment be reserved for patients who meet specific criteria, who are treated at centers with sufficient training and experience, and who are part of a therapeutic trial.

  6. Radionuclides are most appropriate for patients who have several sites of painful osteoblastic metastases (like those that are commonly associated with prostate cancer) that cannot be conveniently or safely treated with EBRT.

  7. Surgical decompression and stabilization plus postoperative radiation therapy should be considered for some patients with single-level spinal cord compression or spinal instability.

    Stephen Lutz, M.D., lead author of the guideline and a radiation oncologist at Blanchard Valley Regional Cancer Center in Findlay, Ohio, said, "Radiation therapy is commonly used to treat bone metastases and has been proven very effective, but with the variety of radiation therapies available and range of successful fractionation schedules, it's important to provide physicians with this guideline to assure they are using the most appropriate methods in treating patients."


    '/>"/>


Contact: Beth Bukata
bethb@astro.org
703-839-7332
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. Senate Committee Advances Disastrous Idaho Health Freedom Act
2. ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies
3. ASTRO awards 17 Advocacy Day travel grants
4. ASTRO publishes supplement on protecting cancer patients by reducing radiation doses, side effects
5. Santa Monica Jury Rejects Claims of Catastrophic Brain Injury From Exposure to Mold; Plaintiff Faces Motions for Attorney Fees and Costs
6. Astrogenetix Narrows in on MRSA Virulence Onboard Discovery
7. A new endoscopic technique for gastrointestinal perforations: the over-the-scope-clip
8. ASTRO president speaks on prostate cancer at MEDCAC meeting
9. ASTRO applauds nomination of Dr. Donald Berwick to head Centers for Medicare and Medicaid Services
10. Outstanding young gastroenterologists receive AGA Foundation
11. Outstanding young gastroenterologists receive AGA Foundation 2010 Research Scholars Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... , ... June 28, 2017 , ... ... management and financial planning assistance to clients in southern Montana, is announcing a ... by Zoo Montana. , The outreach programs offered by Zoo Montana provide students ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... consulting firm servicing communities throughout the greater Cincinnati metropolitan area, is teaming up ... temporary lodgings for families with children receiving treatment in nearby hospitals. , Ronald ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... DrugDev ... study is whether they can trust the sponsor to pay them correctly and on ... sponsors and CROs establish payment strategies that encourage sites to work on their studies. ...
(Date:6/27/2017)... ... 2017 , ... The Congressional Budget Office (CBO) projects that the Better Care ... Protection and Affordable Care Act (ACA), would result in 22 million Americans losing their ... , More than 20 million Americans have gained health insurance under the ACA, and ...
(Date:6/27/2017)... ... , ... A January 18th article on medGadget reports that the ... the year 2024 according to a new report. The article also notes that the ... Los Angeles area clinic Beverly Hills Periodontics & Dental Implant Center says that it ...
Breaking Medicine News(10 mins):
(Date:6/19/2017)... HORSHAM, Pa. , June 19, 2017  Researchers ... announced today that they will host a live, complimentary ... Perspectives from the benchtop to the real world" on ... PM EDT. This webinar will feature ... a rare look into the manipulation techniques abusers use ...
(Date:6/14/2017)... The Bio Supply Management Alliance (BSMA) has ... and the Biomedical Manufacturing Network to advance ... California by providing a platform for ... workforce development. The primary focus of this alliance is ... well as small and mid-sized biomedical companies. ...
(Date:6/11/2017)... June 10, 2017  Eli Lilly and Company (NYSE: ... Phase 3 studies of galcanezumab, an investigational treatment for ... data on several key secondary endpoints for galcanezumab compared ... these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented ... meeting in Boston . ...
Breaking Medicine Technology: